GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Vion Inks Manufacturing Deal for Anticancer Agent

  • Ben Venue Laboratories will manufacture Vion Pharmaceuticals’ Cloretazine, its lead anticancer agent, under a manufacturing agreement. 

    Cloretazine, an alkylating agent, is being evaluated in a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia (AML) and a Phase II trial in elderly patients with previously untreated de novo poor-risk AML.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Sustainability in New Dietary Guidelines

Do you think that sustainability considerations should be incorporated into the new Dietary Guidelines for Americans?

More »